Dallas, TX (PRWEB) March 16, 2015
Rosellini Scientific, a life science private equity firm, announced the formation of Telemend Medical, Inc. The emerging company will be led by Director and CEO Sheneka Rains, who will refine its focus on healthcare delivery models incorporating advanced medical technologies. To form this new entity, Rosellini Scientific completed acquisitions of Elite Biomedical and Integrity Biomedical clinical engineering companies, and then merged these with operations from Grey Owl Dental, a wholly owned subsidiary.
Previously VP of Clinical Engineering at Rosellini Scientific, Rains is experienced in creating solutions and driving operations that reduce costs, while maintaining quality, improving outcomes, and adhering to industry standards. Rains envisions a fully-integrated healthcare system that increases access to patients, supports clinical decisions, and empowers patients to take control of their own health. “In 2015, we will fine-tune our current operations and leverage them to incubate a number of exciting growth initiatives, most notably, tele-psychiatry, IT interoperability, and remote patient monitoring platforms in sub-acute care facilities,” Ms. Rains explained. “The current climate will drive patients to be more independent: spending less time in hospitals and doctors’ offices and more time in control of their own care. We aim for our technology and service systems to be the solution to this change.”
About TeleMend Medical
TeleMend Medical employs proven concepts to optimize healthcare delivery models aimed to improve quality of care, outcomes and to reduce costs. The Company’s momentum comes from its ability to develop solutions ahead of current industry needs. TeleMend Medical will continue to expand its expertise into areas such as information technology, population health, clinical decision support, and data analytics. For more information visit http://www.TeleMend.com
About Rosellini Scientific
Rosellini Scientific invests both expertise and capital in the development, management, and post-market support of medical technology. The company fosters technology development through collaborations with leading researchers, as well as partnerships with pioneering companies and universities. Rosellini Scientific is creating an active market for translational medicine that connects all stakeholders.
Visit http://www.RoselliniScientific.com to learn more.